{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:18:51Z","timestamp":1781273931893,"version":"3.54.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a life-threatening autosomal recessive disease that leads to progressive muscle weakness and atrophy, respiratory insufficiency and scoliosis. SMA is currently the most common monogenic cause of infant mortality. Amazing advancements have been made in the therapeutic options available for these children since 2016. What has also become clear is that the earlier the treatment is administered, the better the clinical outcome. For several reasons, which we will review in this chapter, SMA may be an excellent disease candidate for in utero therapy.<\/jats:p>","DOI":"10.1097\/grf.0000000000000654","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T22:17:24Z","timestamp":1632521844000},"page":"917-925","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Spinal Muscular Atrophy: A Potential Target for In Utero Therapy"],"prefix":"10.1097","volume":"64","author":[{"given":"Caitlin","family":"Baptiste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl C.","family":"De Vivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"R2-20250512","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","article-title":"Newborn and carrier screening for spinal muscular atrophy","volume":"152A","author":"Prior","year":"2010","journal-title":"Am J Med Genet A"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/AOG.0000000000001952","article-title":"Carrier screening for genetic conditions","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00439-002-0828-x","article-title":"Genetic testing and risk assessment for spinal muscular atrophy (SMA)","volume":"111","author":"Ogino","year":"2002","journal-title":"Hum Genet"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1750-3639.2001.tb00395.x","article-title":"Spinal muscular atrophy: present state","volume":"11","author":"Schmalbruch","year":"2001","journal-title":"Brain Pathol"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","volume":"3","author":"Butchbach","year":"2016","journal-title":"Front Mol Biosci"},{"key":"R8-20250512","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3233\/JND-160177","article-title":"Type 0 spinal muscular atrophy: further delineation of prenatal and postnatal features in 16 patients","volume":"3","author":"Grotto","year":"2016","journal-title":"J Neuromuscul Dis"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/fnl.13.58","article-title":"Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond","volume":"9","author":"Monani","year":"2014","journal-title":"Future Neurol"},{"key":"R11-20250512","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","article-title":"The changing natural history of spinal muscular atrophy type 1","volume":"69","author":"Oskoui","year":"2007","journal-title":"Neurology"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"R14-20250512","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl","key":"R18-20250512","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1212\/WNL.94.15_supplement.1828","article-title":"Onasemnogene abeparvovec-xioi gene-replacement therapy for spinal muscular atrophy type 1 (SMA1): phase 3 US study (STR1VE) update (1828)","volume":"94","author":"Day","year":"2020","journal-title":"Neurology"},{"issue":"suppl","key":"R20-20250512","first-page":"S25","article-title":"FIREFISH part 1: 1-year results on motor function in babies with type 1 SMA","volume":"92","author":"Baranelloa","year":"2019","journal-title":"Neurology"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2019.08.017","article-title":"Fetal gene therapy using a single injection of recombinant AAV9 rescued SMA phenotype in mice","volume":"27","author":"Rashnonejad","year":"2019","journal-title":"Mol Ther"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/hum.2011.166","article-title":"Decreasing disease severity in symptomatic, Smn(-\/-); SMN2(+\/+), spinal muscular atrophy mice following scAAV9-SMN delivery","volume":"23","author":"Glascock","year":"2012","journal-title":"Hum Gene Ther"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/GCO.0000000000000444","article-title":"Prenatal transplantation of human amniotic fluid stem cells for spinal muscular atrophy","volume":"30","author":"Peng","year":"2018","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"R26-20250512","doi-asserted-by":"crossref","first-page":"e22948","DOI":"10.1002\/jcla.22948","article-title":"Neurofilament levels in patients with neurological diseases: a comparison of neurofilament light and heavy chain levels","volume":"33","author":"Ku\u0161nierov\u00e1","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/ene.13965","article-title":"Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study","volume":"26","author":"Cuello","year":"2019","journal-title":"Eur J Neurol"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/HYPERTENSIONAHA.117.10314","article-title":"Neurofilament as neuronal injury blood marker in preeclampsia","volume":"71","author":"Evers","year":"2018","journal-title":"Hypertension"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:10:35Z","timestamp":1747062635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000654","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,21]]}}}